GlobeNewswire Inc | Feb 4, 2021 07:00AM EST

February 04, 2021

DURHAM, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021 at 2:00 PM ET.

A live webcast of the presentation will be accessible on the Companys website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations. An archived replay of the webcasts will be available for approximately 30 days following the presentation.

About Precision BioSciences, Inc.Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Companys pipeline consists of multiple off-the-shelf CAR T immunotherapy clinical candidates and severalin vivogene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visitwww.precisionbiosciences.com.

Investor Contact:Alex KellyInterim Chief Financial OfficerAlex.Kelly@precisionbiosciences.com

Media Contact:Maurissa MessierSenior Director, Corporate CommunicationsMaurissa.Messier@precisionbiosciences.com